RU2240349C2 - Способ введения dsрнк или днк, способной к продуцированию dsрнк в c.elegans (варианты), способ негативной регуляции экспрессии интересующего гена в c.elegans (варианты) - Google Patents

Способ введения dsрнк или днк, способной к продуцированию dsрнк в c.elegans (варианты), способ негативной регуляции экспрессии интересующего гена в c.elegans (варианты) Download PDF

Info

Publication number
RU2240349C2
RU2240349C2 RU2000133315/13A RU2000133315A RU2240349C2 RU 2240349 C2 RU2240349 C2 RU 2240349C2 RU 2000133315/13 A RU2000133315/13 A RU 2000133315/13A RU 2000133315 A RU2000133315 A RU 2000133315A RU 2240349 C2 RU2240349 C2 RU 2240349C2
Authority
RU
Russia
Prior art keywords
elegans
polymerase
promoter
promoters
dna sequence
Prior art date
Application number
RU2000133315/13A
Other languages
English (en)
Russian (ru)
Other versions
RU2000133315A (ru
Inventor
Герт ПЛАТИНК (BE)
Герт ПЛАТИНК
Христ ПЛАТТЕУ (BE)
Христ ПЛАТТЕУ
Катрин МОРТЬЕ (BE)
Катрин МОРТЬЕ
Тирри БОГАРТ (BE)
Тирри БОГАРТ
Original Assignee
Девген Н.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26313977&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2240349(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9814536.0A external-priority patent/GB9814536D0/en
Application filed by Девген Н.В. filed Critical Девген Н.В.
Publication of RU2000133315A publication Critical patent/RU2000133315A/ru
Application granted granted Critical
Publication of RU2240349C2 publication Critical patent/RU2240349C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/02—Preparation of hybrid cells by fusion of two or more cells, e.g. protoplast fusion
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1079—Screening libraries by altering the phenotype or phenotypic trait of the host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1093—General methods of preparing gene libraries, not provided for in other subgroups
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8216—Methods for controlling, regulating or enhancing expression of transgenes in plant cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8216—Methods for controlling, regulating or enhancing expression of transgenes in plant cells
    • C12N15/8218—Antisense, co-suppression, viral induced gene silencing [VIGS], post-transcriptional induced gene silencing [PTGS]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8261—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield
    • C12N15/8271—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield for stress resistance, e.g. heavy metal resistance
    • C12N15/8279—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield for stress resistance, e.g. heavy metal resistance for biotic stress resistance, pathogen resistance, disease resistance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8261—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield
    • C12N15/8271—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield for stress resistance, e.g. heavy metal resistance
    • C12N15/8279—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield for stress resistance, e.g. heavy metal resistance for biotic stress resistance, pathogen resistance, disease resistance
    • C12N15/8285—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield for stress resistance, e.g. heavy metal resistance for biotic stress resistance, pathogen resistance, disease resistance for nematode resistance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6869—Methods for sequencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10211—Podoviridae
    • C12N2795/10241—Use of virus, viral particle or viral elements as a vector
    • C12N2795/10243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/40—Systems of functionally co-operating vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A40/00—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production
    • Y02A40/10—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production in agriculture
    • Y02A40/146—Genetically Modified [GMO] plants, e.g. transgenic plants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Virology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Catching Or Destruction (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
RU2000133315/13A 1998-07-03 1999-07-02 Способ введения dsрнк или днк, способной к продуцированию dsрнк в c.elegans (варианты), способ негативной регуляции экспрессии интересующего гена в c.elegans (варианты) RU2240349C2 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9814536.0A GB9814536D0 (en) 1998-07-03 1998-07-03 Characterisation of gene function using double stranded rna inhibition
GB9814536.0 1998-07-03
GBGB9827152.1A GB9827152D0 (en) 1998-07-03 1998-12-09 Characterisation of gene function using double stranded rna inhibition
GB9827152.1 1998-12-09

Publications (2)

Publication Number Publication Date
RU2000133315A RU2000133315A (ru) 2003-02-20
RU2240349C2 true RU2240349C2 (ru) 2004-11-20

Family

ID=26313977

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2000133315/13A RU2240349C2 (ru) 1998-07-03 1999-07-02 Способ введения dsрнк или днк, способной к продуцированию dsрнк в c.elegans (варианты), способ негативной регуляции экспрессии интересующего гена в c.elegans (варианты)

Country Status (27)

Country Link
US (3) US20030061626A1 (enExample)
EP (5) EP2045336A3 (enExample)
JP (3) JP4353639B2 (enExample)
KR (4) KR20070041607A (enExample)
CN (3) CN1900319A (enExample)
AT (2) ATE419383T1 (enExample)
AU (1) AU769223B2 (enExample)
BR (1) BR9911802A (enExample)
CA (2) CA2332619C (enExample)
CY (2) CY1108920T1 (enExample)
CZ (2) CZ303494B6 (enExample)
DE (5) DE1093526T1 (enExample)
DK (2) DK1484415T3 (enExample)
ES (2) ES2320527T5 (enExample)
GB (4) GB9827152D0 (enExample)
HU (1) HU230602B1 (enExample)
IL (3) IL140467A0 (enExample)
IN (2) IN2001DE00006A (enExample)
IS (1) IS2816B (enExample)
MX (1) MX234065B (enExample)
NO (1) NO327729B1 (enExample)
NZ (1) NZ509182A (enExample)
PL (3) PL213379B1 (enExample)
PT (2) PT1484415E (enExample)
RU (1) RU2240349C2 (enExample)
WO (1) WO2000001846A2 (enExample)
ZA (1) ZA200007653B (enExample)

Families Citing this family (257)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
AUPP249298A0 (en) * 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
CA2513336A1 (en) 1998-03-20 1999-09-30 Benitec Australia Ltd. Control of gene expression in a non-human eukaryotic cell, tissue or organ
GB9827152D0 (en) * 1998-07-03 1999-02-03 Devgen Nv Characterisation of gene function using double stranded rna inhibition
AU776150B2 (en) * 1999-01-28 2004-08-26 Medical College Of Georgia Research Institute, Inc. Composition and method for (in vivo) and (in vitro) attenuation of gene expression using double stranded RNA
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
US7601494B2 (en) 1999-03-17 2009-10-13 The University Of North Carolina At Chapel Hill Method of screening candidate compounds for susceptibility to biliary excretion
KR20070118315A (ko) * 1999-04-21 2007-12-14 와이어쓰 폴리뉴클레오티드 서열의 기능을 억제하기 위한 조성물
US20040138168A1 (en) * 1999-04-21 2004-07-15 Wyeth Methods and compositions for inhibiting the function of polynucleotide sequences
US6924109B2 (en) * 1999-07-30 2005-08-02 Agy Therapeutics, Inc. High-throughput transcriptome and functional validation analysis
US6423885B1 (en) 1999-08-13 2002-07-23 Commonwealth Scientific And Industrial Research Organization (Csiro) Methods for obtaining modified phenotypes in plant cells
HK1047109A1 (zh) 1999-10-15 2003-02-07 University Of Massachusetts 作为指定基因干预工具的rna干预轨迹基因
GB9927444D0 (en) * 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
US7829693B2 (en) 1999-11-24 2010-11-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a target gene
DE10100586C1 (de) 2001-01-09 2002-04-11 Ribopharma Ag Verfahren zur Hemmung der Expression eines Ziegens
GB9930691D0 (en) * 1999-12-24 2000-02-16 Devgen Nv Improvements relating to double-stranded RNA inhibition
US7491805B2 (en) 2001-05-18 2009-02-17 Sirna Therapeutics, Inc. Conjugates and compositions for cellular delivery
US8202979B2 (en) 2002-02-20 2012-06-19 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid
US7833992B2 (en) 2001-05-18 2010-11-16 Merck Sharpe & Dohme Conjugates and compositions for cellular delivery
US8273866B2 (en) 2002-02-20 2012-09-25 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SINA)
JP2003526367A (ja) 2000-03-16 2003-09-09 ジェネティカ インコーポレイテッド Ｒｎａ干渉の方法とｒｎａ干渉組成物
US8202846B2 (en) 2000-03-16 2012-06-19 Cold Spring Harbor Laboratory Methods and compositions for RNA interference
KR101215789B1 (ko) 2000-03-30 2012-12-26 화이트헤드 인스티튜트 포 바이오메디칼 리서치 Ｒｎａ 간섭의 ｒｎａ 서열 특이적인 매개체
GB0012233D0 (en) 2000-05-19 2000-07-12 Devgen Nv Vector constructs
US7083947B2 (en) 2000-05-19 2006-08-01 Devgen Nv Assay techniques using nematode worms
GB2362383B (en) * 2000-05-19 2003-12-31 Devgen Nv Gene expression system
GB0012229D0 (en) 2000-05-19 2000-07-12 Devgen Nv Lipid uptake assays
WO2001096584A2 (en) * 2000-06-12 2001-12-20 Akkadix Corporation Materials and methods for the control of nematodes
US20030190635A1 (en) * 2002-02-20 2003-10-09 Mcswiggen James A. RNA interference mediated treatment of Alzheimer's disease using short interfering RNA
SI1407044T2 (en) 2000-12-01 2018-03-30 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Rna interference mediating small rna molecules
US7423142B2 (en) 2001-01-09 2008-09-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of anti-apoptotic genes
US7767802B2 (en) 2001-01-09 2010-08-03 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of anti-apoptotic genes
ATE455863T1 (de) * 2001-01-25 2010-02-15 Virxsys Corp Methoden und zusammensetzungen zur identifikation von gen-funktion
WO2002059294A1 (en) 2001-01-26 2002-08-01 Commonwealth Scientific And Industrial Research O Rganisation Methods and means for producing efficient silencing construct using recombinational cloning
CA2369944A1 (en) 2001-01-31 2002-07-31 Nucleonics Inc. Use of post-transcriptional gene silencing for identifying nucleic acid sequences that modulate the function of a cell
WO2002063037A2 (en) * 2001-02-02 2002-08-15 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Method for identifying functional nucleic acids
US7517864B2 (en) 2001-05-18 2009-04-14 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US9994853B2 (en) 2001-05-18 2018-06-12 Sirna Therapeutics, Inc. Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
US20050148530A1 (en) 2002-02-20 2005-07-07 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
WO2003070887A2 (en) * 2002-02-20 2003-08-28 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF POLYCOMB GROUP PROTEIN EZH2 GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US7109165B2 (en) 2001-05-18 2006-09-19 Sirna Therapeutics, Inc. Conjugates and compositions for cellular delivery
EP3231445A1 (en) 2001-05-18 2017-10-18 Sirna Therapeutics, Inc. Conjugates and compositions for cellular delivery
ES2566561T3 (es) 2001-07-12 2016-04-13 University Of Massachusetts Producción in vivo de ARN pequeños de interferencia que median el silenciamiento génico
US7612194B2 (en) * 2001-07-24 2009-11-03 Monsanto Technology Llc Nucleic acid sequences from Diabrotica virgifera virgifera LeConte and uses thereof
DE60236095D1 (de) 2001-08-31 2010-06-02 Riken Wako PFLANZENSYSTEM ZUR UMFASSENDEN GENFUNKTIONSANALYSE UNTER VERWENDUNG EINER VOLLÄNGEN-cDNA
US7745418B2 (en) 2001-10-12 2010-06-29 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting viral replication
DE10163098B4 (de) 2001-10-12 2005-06-02 Alnylam Europe Ag Verfahren zur Hemmung der Replikation von Viren
US20030150017A1 (en) * 2001-11-07 2003-08-07 Mesa Jose Ramon Botella Method for facilitating pathogen resistance
DE10202419A1 (de) 2002-01-22 2003-08-07 Ribopharma Ag Verfahren zur Hemmung der Expression eines durch eine Chromosomen-Aberration entstandenen Zielgens
ATE443133T1 (de) 2002-02-01 2009-10-15 Life Technologies Corp Oligonukleotidzusammensetzungen mit verbesserter effizienz
WO2003064621A2 (en) * 2002-02-01 2003-08-07 Ambion, Inc. HIGH POTENCY siRNAS FOR REDUCING THE EXPRESSION OF TARGET GENES
US20060009409A1 (en) 2002-02-01 2006-01-12 Woolf Tod M Double-stranded oligonucleotides
AU2003219833A1 (en) * 2002-02-20 2003-09-09 Sirna Therapeutics Inc. RNA INTERFERENCE MEDIATED INHIBITION OF CHROMOSOME TRANSLOCATION GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
WO2003070966A2 (en) * 2002-02-20 2003-08-28 Sirna Therapeutics, Inc RNA INTERFERENCE MEDIATED TARGET DISCOVERY AND TARGET VALIDATION USING SHORT INTERFERING NUCLEIC ACID (siNA)
EP1432724A4 (en) 2002-02-20 2006-02-01 Sirna Therapeutics Inc INTERFERENCE MEDIATION INHIBITION OF GENE RNA FROM MAP KINASE
US9181551B2 (en) 2002-02-20 2015-11-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US7667029B2 (en) 2002-02-20 2010-02-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of checkpoint kinase-1 (CHK-1) gene expression using short interfering nucleic acid (siNA)
AU2003216255A1 (en) * 2002-02-20 2003-09-09 Ribozyme Pharmaceuticals, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF MDR P-GLYCOPROTEIN GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
AU2003213057A1 (en) * 2002-02-20 2003-09-09 Ribozyme Pharmaceuticals, Incoporated Rna interference mediated inhibition of checkpoint kinase-1 (chk-1) gene expression using short interfering nucleic acid
US9657294B2 (en) 2002-02-20 2017-05-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
AU2003228667A1 (en) * 2002-04-22 2003-12-19 Sirna Therapeutics Inc. Nucleic acid mediated disruption of hiv fusogenic peptide interactions
US20040180438A1 (en) 2002-04-26 2004-09-16 Pachuk Catherine J. Methods and compositions for silencing genes without inducing toxicity
WO2003095652A2 (de) * 2002-05-08 2003-11-20 Xantos Biomedicine Ag EXPRESSIONSKONSTRUKTE ZUR HERSTELLUNG VON DOPPELSTRANG (ds) RNA UND DEREN ANWENDUNG
WO2003100094A2 (en) * 2002-05-23 2003-12-04 Devgen Nv Method for determining the influence of a compound on cholesterol transport
US20100009856A1 (en) * 2002-06-21 2010-01-14 Sinogenomax Sompany LTD. Randomized dna libraries and double-stranded rna libraries, use and method of production thereof
WO2004005485A2 (en) * 2002-07-10 2004-01-15 Kansas State University Research Foundation Compositions and methods for controlling parasitic nematodes
US7655790B2 (en) 2002-07-12 2010-02-02 Sirna Therapeutics, Inc. Deprotection and purification of oligonucleotides and their derivatives
KR101201664B1 (ko) 2002-08-05 2012-11-15 사일런스 테라퓨틱스 아게 신규한 형태의 간섭 ｒｎａ 분자
WO2004014933A1 (en) 2002-08-07 2004-02-19 University Of Massachusetts Compositions for rna interference and methods of use thereof
WO2004022782A2 (en) * 2002-09-04 2004-03-18 Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin Compositions and methods for tissue specific or inducible inhibition of gene expression
US7956176B2 (en) 2002-09-05 2011-06-07 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
CA2507189C (en) 2002-11-27 2018-06-12 Sequenom, Inc. Fragmentation-based methods and systems for sequence variation detection and discovery
WO2004056982A2 (en) * 2002-12-23 2004-07-08 Devgen Nv Kinase sequences
EP1622572B1 (en) 2003-04-30 2017-12-20 Sirna Therapeutics, Inc. Conjugates and compositions for cellular delivery
IL155783A (en) 2003-05-05 2010-11-30 Technion Res & Dev Foundation Multicellular systems of multi-potential embryonic human stem cells and cancer cells and their use
US7619068B2 (en) 2003-05-09 2009-11-17 Diadexus, Inc. Ovr110 antibody compositions and methods of use
EP1644494A2 (en) * 2003-06-17 2006-04-12 Devgen NV Alcohol dehydrogenase sequences useful for developing compounds for the prevention and/or treatment of metabolic diseases
US9394565B2 (en) 2003-09-05 2016-07-19 Agena Bioscience, Inc. Allele-specific sequence variation analysis
ES2374529T3 (es) * 2003-11-17 2012-02-17 Commonwealth Scientific And Industrial Research Organisation Resistencia a insectos usando inhibición de la expresión génica.
EP2395112B1 (en) 2003-12-31 2017-02-15 The Penn State Research Foundation Methods for predicting and overcoming resistance to chemotherapy in ovarian cancer and for predicting colon cancer occurrence
ATE452188T1 (de) 2004-02-10 2010-01-15 Sirna Therapeutics Inc Rna-interferenz-vermittelte hemmung der genexpression unter verwendung multifunktioneller sina (short interfering nucleic acid)
WO2005078848A2 (en) 2004-02-11 2005-08-25 University Of Tennessee Research Foundation Inhibition of tumor growth and invasion by anti-matrix metalloproteinase dnazymes
US7622301B2 (en) * 2004-02-24 2009-11-24 Basf Plant Science Gmbh Compositions and methods using RNA interference for control of nematodes
WO2006074418A2 (en) 2005-01-07 2006-07-13 Diadexus, Inc. Ovr110 antibody compositions and methods of use
US7608394B2 (en) * 2004-03-26 2009-10-27 Sequenom, Inc. Methods and compositions for phenotype identification based on nucleic acid methylation
CN101233240A (zh) 2004-03-26 2008-07-30 斯昆诺有限公司 与质量分析结合的甲基化特异性扩增产物的碱基特异性切割
CA2562038C (en) 2004-04-02 2017-04-25 The Regents Of The University Of California Methods and compositions for treating and preventing disease associated with .alpha.v.beta.5 integrin
AR048685A1 (es) 2004-04-09 2006-05-17 Monsanto Technology Llc Metodos para el control de infestaciones de insectos en plantas.
WO2005105157A2 (en) 2004-04-23 2005-11-10 The Trustees Of Columbia University In The City Ofnew York INHIBITION OF HAIRLESS PROTEIN mRNA
US10508277B2 (en) 2004-05-24 2019-12-17 Sirna Therapeutics, Inc. Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
WO2006009575A1 (en) 2004-06-22 2006-01-26 The Board Of Trustees Of The University Of Illinois METHODS OF INHIBITING TUMOR CELL PROLIFERATION WITH FOXM1 siRNA
US7968762B2 (en) 2004-07-13 2011-06-28 Van Andel Research Institute Immune-compromised transgenic mice expressing human hepatocyte growth factor (hHGF)
US20100132058A1 (en) 2004-07-23 2010-05-27 Diatchenko Luda B Methods and materials for determining pain sensitivity and predicting and treating related disorders
ATE518954T1 (de) 2004-08-18 2011-08-15 Lorus Therapeutics Inc Kleine interferierende rna-moleküle gegen ribonukleotidreduktase und ihre verwendungen
US7713735B2 (en) * 2004-09-24 2010-05-11 J.R. Simplot Company Gene silencing
US20060247197A1 (en) 2004-10-04 2006-11-02 Van De Craen Marc Method for down-regulating gene expression in fungi
MX2007004310A (es) * 2004-10-13 2007-06-18 Univ Georgia Res Found Plantas transgenicas resistentes a nematodos.
ES2444001T3 (es) 2004-10-21 2014-02-21 Venganza Inc. Procedimientos y materiales para conferir resistencia a plagas y patógenos de plantas
US8772254B2 (en) 2004-10-25 2014-07-08 Devgen N.V. Method and constructs for delivering double stranded RNA to pest organisms
EP2330203A3 (en) 2004-10-25 2011-10-05 Devgen NV Rna constructs
US8519225B2 (en) 2006-02-10 2013-08-27 Monsanto Technology Llc Identification and use of target genes for control of plant parasitic nematodes
US8088976B2 (en) * 2005-02-24 2012-01-03 Monsanto Technology Llc Methods for genetic control of plant pest infestation and compositions thereof
DE202005004135U1 (de) * 2005-03-11 2005-05-19 Klocke Verpackungs-Service Gmbh Mehrkomponentenverpackung mit Applikator
EP1866414B9 (en) 2005-03-31 2012-10-03 Calando Pharmaceuticals, Inc. Inhibitors of ribonucleotide reductase subunit 2 and uses thereof
CA2605508A1 (en) 2005-05-12 2006-11-23 Wisconsin Alumni Research Foundation Blockade of pin1 prevents cytokine production by activated immune cells
EP1907546A2 (en) 2005-05-31 2008-04-09 Devgen N.V. Rnai for control of insects and arachnids
US8703769B2 (en) 2005-07-15 2014-04-22 The University Of North Carolina At Chapel Hill Use of EGFR inhibitors to prevent or treat obesity
ES2557512T3 (es) 2005-09-16 2016-01-26 Devgen N.V. Métodos basados en plantas transgénicas para plagas de plantas usando ARNi
ES2568933T3 (es) 2005-09-16 2016-05-05 Devgen N.V. ARNbc como agente de control de insectos
PL2431473T3 (pl) 2005-09-16 2017-05-31 Monsanto Technology Llc Sposoby genetycznej kontroli inwazji owadów u roślin i kompozycje do tego przeznaczone
US9708619B2 (en) 2005-09-20 2017-07-18 Basf Plant Science Gmbh Methods for controlling gene expression using ta-siRNA
US9286469B2 (en) * 2005-12-16 2016-03-15 Cisco Technology, Inc. Methods and apparatus providing computer and network security utilizing probabilistic signature generation
EP1974041A2 (en) 2006-01-06 2008-10-01 University Of Georgia Research Foundation, Inc. Cyst nematode resistant transgenic plants
US8906876B2 (en) 2006-01-12 2014-12-09 Devgen Nv Methods for controlling pests using RNAi
EP2347759B1 (en) 2006-01-12 2017-10-18 deVGen N.V. Methods for controlling pests using RNAi
EP2377939A3 (en) 2006-01-12 2012-01-18 deVGen N.V. Transgenic plant-based methods for plant pests using RNAi
US20080022423A1 (en) * 2006-02-03 2008-01-24 Monsanto Technology Llc IN PLANTA RNAi CONTROL OF FUNGI
CN105385679B (zh) * 2006-02-13 2020-05-26 孟山都技术有限公司 选择和稳定dsRNA构建体
US20100068172A1 (en) * 2006-03-16 2010-03-18 Devgen N.V. Nematode Control
WO2007123777A2 (en) 2006-03-30 2007-11-01 Duke University Inhibition of hif-1 activation for anti-tumor and anti-inflammatory responses
PL216037B1 (pl) * 2006-06-09 2014-02-28 Inst Biotechnologii I Antybiotykow Kaseta ekspresyjna, zastosowanie kasety ekspresyjnej, wektor, komórka gospodarza oraz sposób otrzymywania polipeptydu
CN103275980B (zh) 2006-07-11 2015-09-09 罗格斯新泽西州立大学 抗体、融合蛋白以及组合物
US7666423B2 (en) 2006-07-28 2010-02-23 Children's Memorial Hospital Methods of inhibiting tumor cell aggressiveness using the microenvironment of human embryonic stem cells
CA2670696A1 (en) 2006-11-27 2008-06-05 Diadexus, Inc. Ovr110 antibody compositions and methods of use
CN101195821A (zh) * 2006-12-04 2008-06-11 中国科学院上海生命科学研究院 利用RNAi技术改良植物抗虫性的方法
WO2008094370A2 (en) 2006-12-22 2008-08-07 University Of Utah Research Foundation Method of detecting ocular diseases and pathologic conditions and treatment of same
CA2676143A1 (en) 2007-01-26 2008-07-31 University Of Louisville Research Foundation, Inc. Modification of exosomal components for use as a vaccine
US20080184391A1 (en) * 2007-01-29 2008-07-31 Kuppuswamy Subramaniam Pathogen resistant transgenic plants, associated nucleic acids and techniques involving the same
EP2115141A4 (en) 2007-02-20 2010-08-04 Monsanto Technology Llc miRNA FROM INVERTEBRATES
BRPI0809130A8 (pt) 2007-03-21 2021-11-03 Brookhaven Science Ass Llc Composições combinadas hairpin-antissenso e métodos para modulação da expressão
EP2377952A1 (en) 2007-04-26 2011-10-19 Ludwig Institute For Cancer Research Methods for diagnosing and treating astrocytomas
WO2008137115A1 (en) 2007-05-03 2008-11-13 The Brigham And Women's Hospital, Inc. Multipotent stem cells and uses thereof
US8097422B2 (en) 2007-06-20 2012-01-17 Salk Institute For Biological Studies Kir channel modulators
US20110111481A1 (en) * 2007-06-29 2011-05-12 Chiang Li ENABLING THE USE OF LONG dsRNA FOR GENE TARGETING IN MAMMALIAN AND OTHER SELECTED ANIMAL CELLS
US9689031B2 (en) 2007-07-14 2017-06-27 Ionian Technologies, Inc. Nicking and extension amplification reaction for the exponential amplification of nucleic acids
WO2009012263A2 (en) 2007-07-18 2009-01-22 The Trustees Of Columbia University In The City Of New York Tissue-specific micrornas and compositions and uses thereof
ES2651911T3 (es) 2007-08-14 2018-01-30 Commonwealth Scientific And Industrial Research Organisation Métodos mejorados de silenciamiento génico
KR101142209B1 (ko) 2007-09-22 2012-05-04 재단법인서울대학교산학협력재단 섭취 ＲＮＡｉ를 이용한 꼬마선충에서 두 유전자의동시발현 억제방법
US7968525B1 (en) 2007-12-03 2011-06-28 University Of Florida Research Foundation, Inc. Use of RNA interference to validate new termiticide target sites and a method of termite control
JP2011516065A (ja) 2008-04-04 2011-05-26 カランド ファーマシューティカルズ， インコーポレイテッド Ｅｐａｓ１阻害剤の組成物および使用
WO2009126896A2 (en) 2008-04-10 2009-10-15 Monsanto Technology Llc Methods and compositions for root knot nematode control
GB0807018D0 (en) 2008-04-17 2008-05-21 Fusion Antibodies Ltd Antibodies and treatment
US9289475B2 (en) 2008-11-06 2016-03-22 The Johns Hopkins University Treatment of chronic inflammatory respiratory disorders
EP2687609B1 (en) 2008-11-10 2017-01-04 The United States of America, as represented by The Secretary, Department of Health and Human Services Method for treating solid tumor
DK2379722T3 (da) 2008-12-16 2017-01-02 C-Lecta Gmbh Ekspressionsvektor
WO2010074783A1 (en) 2008-12-23 2010-07-01 The Trustees Of Columbia University In The City Of New York Phosphodiesterase inhibitors and uses thereof
EP2379076B1 (en) 2008-12-23 2014-11-12 The Trustees of Columbia University in the City of New York Phosphodiesterase inhibitors and uses thereof
WO2010107952A2 (en) 2009-03-19 2010-09-23 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF CONNECTIVE TISSUE GROWTH FACTOR (CTGF) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
EA201171144A1 (ru) 2009-03-19 2012-04-30 Мерк Шарп Энд Домэ Корп. ОПОСРЕДОВАННОЕ РНК-ИНТЕРФЕРЕНЦИЕЙ ИНГИБИРОВАНИЕ ЭКСПРЕССИИ ГЕНА ГОМОЛОГА 1 BTB И CNC, ОСНОВНОГО ФАКТОРА ТРАНСКРИПЦИИ С ЛЕЙЦИНОВОЙ МОЛНИЕЙ 1 (Bach1) С ИСПОЛЬЗОВАНИЕМ МАЛОЙ ИНТЕРФЕРИРУЮЩЕЙ НУКЛЕИНОВОЙ КИСЛОТЫ (миНК)
US20120029054A1 (en) 2009-03-19 2012-02-02 Merck Sharp & Dohme Corp. RNA Interference Mediated Inhibition of GATA Binding Protein 3 (GATA3) Gene Expression Using Short Intefering Nucleic Acid (siNA)
US20120035247A1 (en) 2009-03-19 2012-02-09 Merck Sharp & Dohme Corp. RNA Interference Mediated Inhibition of Signal Transducer and Activator of Transcription 6 (STAT6) Gene Expression Using Short Interfering Nucleic Acid (siNA)
EP2411520A2 (en) 2009-03-27 2012-02-01 Merck Sharp&Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF THE THYMIC STROMAL LYMPHOPOIETIN (TSLP) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
WO2010111468A2 (en) 2009-03-27 2010-09-30 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF THE NERVE GROWTH FACTOR BETA CHAIN (NGFß) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA)
US20120022142A1 (en) 2009-03-27 2012-01-26 Merck Sharp & Dohme Corp. RNA Interference Mediated Inhibition of Signal Transducer and Activator of Transcription 1 (STAT1) Gene Expression Using Short Interfering Nucleic Acid (siNA)
AU2010229847A1 (en) 2009-03-27 2011-10-13 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of the intercellular adhesion molecule 1 (ICAM-1)gene expression using short interfering nucleic acid (siNA)
WO2010111464A1 (en) 2009-03-27 2010-09-30 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF APOPTOSIS SIGNAL-REGULATING KINASE 1 (ASK1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US20100257634A1 (en) * 2009-04-03 2010-10-07 Venganza Inc. Bioassay for gene silencing constructs
US8283332B2 (en) 2009-04-17 2012-10-09 University Of Louisville Research Foundation, Inc. PFKFB4 inhibitors and methods of using the same
EP2258858A1 (en) 2009-06-05 2010-12-08 Universitätsklinikum Freiburg Transgenic LSD1 animal model for cancer
HUE026708T2 (en) 2009-07-14 2016-07-28 Mayo Foundation Peptide-mediated, non-covalent delivery of active substances in blood glucose
CN102481347A (zh) 2009-07-24 2012-05-30 加州大学董事会 治疗和预防整合素αvβ5相关疾病的方法及组合物
MX2012002548A (es) 2009-08-28 2012-04-10 Du Pont Composiciones y metodos para controlar plagas de insectos.
EP2509628B1 (en) 2009-12-07 2017-10-25 The Johns Hopkins University Sr-bi as a predictor of human female infertility and responsiveness to treatment
ES2562499T3 (es) 2009-12-09 2016-03-04 Nitto Denko Corporation Modulación de la expresión de HSP47
JP6093180B2 (ja) 2009-12-10 2017-03-08 トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク ヒストンアセチルトランスフェラーゼ活性化剤及びその使用
US10640457B2 (en) 2009-12-10 2020-05-05 The Trustees Of Columbia University In The City Of New York Histone acetyltransferase activators and uses thereof
BR112012014760A2 (pt) 2009-12-18 2016-06-14 Novartis Ag "composições orgânicas para tratar doenças relacionadas a hsf1, bem como seu uso"
SG10201407996PA (en) 2009-12-23 2015-01-29 Novartis Ag Lipids, lipid compositions, and methods of using them
WO2011094345A1 (en) 2010-01-26 2011-08-04 National Jewish Health Methods and compositions for risk prediction, diagnosis, prognosis, and treatment of pulmonary disorders
IN2012DN06588A (enExample) 2010-02-10 2015-10-23 Novartis Ag
EP3190187A1 (en) 2010-05-21 2017-07-12 Peptimed, Inc. Reagents and methods for treating cancer
GB201009601D0 (en) 2010-06-08 2010-07-21 Devgen Private Ltd Method for down-grading gene expression in fungi
US9168297B2 (en) 2010-06-23 2015-10-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Regulation of skin pigmentation by neuregulin-1 (NRG-1)
US8518907B2 (en) 2010-08-02 2013-08-27 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA)
EP3587574B1 (en) 2010-08-17 2022-03-16 Sirna Therapeutics, Inc. Rna interference mediated inhibition of hepatitis b virus (hbv) gene expression using short interfering nucleic acid (sina)
US9243246B2 (en) 2010-08-24 2016-01-26 Sirna Therapeutics, Inc. Single-stranded RNAi agents containing an internal, non-nucleic acid spacer
US9233997B2 (en) 2010-08-26 2016-01-12 Sirna Therapeutics, Inc. RNA interference mediated inhibition of prolyl hydroxylase domain 2 (PHD2) gene expression using short interfering nucleic acid (siNA)
US20140134231A1 (en) 2010-10-11 2014-05-15 Sanford-Burnham Medical Research Institute Mir-211 expression and related pathways in human melanoma
BR112013009196A2 (pt) 2010-10-15 2020-08-25 The Trustees Of Columbia University In The City Of New York usos de polipeptídeo para redução da aquisição de ácido graxo e da ingestão de alimento, bem como para promoção de saciedade relacionados à obesidade
DK2632472T3 (en) 2010-10-29 2018-03-19 Sirna Therapeutics Inc RNA INTERFERENCE-MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERRING NUCLEIC ACIDS (SINA)
WO2012061443A2 (en) 2010-11-01 2012-05-10 NanoOncology, Inc. Compositions of a peptide-based system for cell-specific targeting
US9198911B2 (en) 2010-11-02 2015-12-01 The Trustees Of Columbia University In The City Of New York Methods for treating hair loss disorders
KR101913293B1 (ko) 2010-11-02 2018-10-30 더 트러스티스 오브 콜롬비아 유니버시티 인 더 시티 오브 뉴욕 탈모 질환의 치료 방법
US9150926B2 (en) 2010-12-06 2015-10-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Diagnosis and treatment of adrenocortical tumors using human microRNA-483
WO2012078536A2 (en) 2010-12-06 2012-06-14 Quark Pharmaceuticals, Inc. Double stranded oligonucleotide compounds comprising positional modifications
US9969677B2 (en) 2010-12-22 2018-05-15 The Trustees Of Columbia University In The City Of New York Histone acetyltransferase modulators and uses thereof
US9205100B2 (en) 2011-03-03 2015-12-08 Quark Pharmaceuticals, Inc. Compositions and methods for treating lung disease and injury
US10196637B2 (en) 2011-06-08 2019-02-05 Nitto Denko Corporation Retinoid-lipid drug carrier
TWI658830B (zh) 2011-06-08 2019-05-11 日東電工股份有限公司 Ｈｓｐ47表現調控強化用類視色素脂質體
EP2750767A4 (en) 2011-09-02 2015-10-14 Univ Columbia CAMKII, IP3R, CALCINEURIN, P38 AND MK2 / 3 INHIBITORS FOR THE TREATMENT OF METABOLISM DISORDER IN CONNECTION WITH ADIPOSITAS
US9352312B2 (en) 2011-09-23 2016-05-31 Alere Switzerland Gmbh System and apparatus for reactions
CN108373506A (zh) 2011-10-14 2018-08-07 霍夫曼-拉罗奇有限公司 抗HtrA1抗体及使用方法
EP3597644B1 (en) 2011-10-18 2021-09-29 Dicerna Pharmaceuticals, Inc. Amine cationic lipids and uses thereof
AU2012332517B9 (en) 2011-11-03 2017-08-10 Quark Pharmaceuticals, Inc. Methods and compositions for neuroprotection
ES2694681T3 (es) 2012-03-29 2018-12-26 The Trustees Of Columbia University In The City Of New York Métodos para tratar trastornos de pérdida capilar
CN104395474A (zh) 2012-04-20 2015-03-04 富优基尼以色列股份有限公司 青铜蝽防治剂
US20150082490A1 (en) 2012-04-23 2015-03-19 Futuragene Israel Ltd. Glycaspis Brimblecombei Control Agents
US20150299696A1 (en) 2012-05-02 2015-10-22 Sirna Therapeutics, Inc. SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
ES2817897T3 (es) 2012-07-23 2021-04-08 La Jolla Inst Allergy & Immunology PTPRS y proteoglicanos en enfermedad autoinmune
CN104903449A (zh) 2012-10-03 2015-09-09 富优基尼以色列股份有限公司 瘿蜂防治剂
CA2886120A1 (en) 2012-10-08 2014-04-17 St. Jude Children's Research Hospital Therapies based on control of regulatory t cell stability and function via a neuropilin-1:semaphorin axis
US9920316B2 (en) 2013-03-14 2018-03-20 Pioneer Hi-Bred International, Inc. Compositions and methods to control insect pests
AU2014236947A1 (en) 2013-03-15 2015-09-03 The Trustees Of Columbia University In The City Of New York Fusion proteins and methods thereof
EP2810952A1 (en) 2013-06-03 2014-12-10 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Novel pest control methods
KR20160027971A (ko) 2013-07-03 2016-03-10 시티 오브 호프 항암 병용제
WO2015054451A1 (en) 2013-10-09 2015-04-16 The United States Of America As Represented By The Secretary Department Of Health And Human Services Detection of hepatitis delta virus (hdv) for the diagnosis and treatment of sjögren's syndrome and lymphoma
WO2015070158A1 (en) 2013-11-11 2015-05-14 Sirna Therapeutics, Inc. Systemic delivery of myostatin short interfering nucleic acids (sina) conjugated to a lipophilic moiety
US9682123B2 (en) 2013-12-20 2017-06-20 The Trustees Of Columbia University In The City Of New York Methods of treating metabolic disease
EP3088001B1 (en) 2013-12-27 2020-02-12 National University Corporation Kochi University Anti-lipolysis stimulated liporotein receptor antibodies for treatment of ovarian cancer
JP6778175B2 (ja) 2014-07-16 2020-10-28 ノバルティス アーゲー 脂質ナノ粒子ホスト中に核酸を封入する方法
WO2016059187A1 (en) * 2014-10-16 2016-04-21 Universite De Strasbourg Method of capturing and identifying novel rnas
AU2015346281B2 (en) 2014-11-12 2021-12-02 Nmc, Inc. Transgenic plants with engineered redox sensitive modulation of photosynthetic antenna complex pigments and methods for making the same
EP3925979A3 (en) 2014-12-23 2022-03-23 The Trustees of Columbia University in the City of New York Fgfr-tacc fusion proteins and methods thereof
US10264976B2 (en) 2014-12-26 2019-04-23 The University Of Akron Biocompatible flavonoid compounds for organelle and cell imaging
US10584144B2 (en) 2015-03-09 2020-03-10 University Of Kentucky Research Foundation RNA nanoparticles for brain tumor treatment
US11085044B2 (en) 2015-03-09 2021-08-10 University Of Kentucky Research Foundation miRNA for treatment of breast cancer
WO2016145003A1 (en) 2015-03-09 2016-09-15 University Of Kentucky Research Foundation Rna nanoparticle for treatment of gastric cancer
US11279768B1 (en) 2015-04-03 2022-03-22 Precision Biologics, Inc. Anti-cancer antibodies, combination therapies, and uses thereof
WO2016168784A2 (en) 2015-04-17 2016-10-20 University Of Kentucky Research Foundation Rna nanoparticles and method of use thereof
WO2016176617A2 (en) 2015-04-29 2016-11-03 New York University Method for treating high-grade gliomas
EP3313420B1 (en) 2015-06-25 2024-03-13 The Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion, enrichment, and maintenance
US10072065B2 (en) 2015-08-24 2018-09-11 Mayo Foundation For Medical Education And Research Peptide-mediated delivery of immunoglobulins across the blood-brain barrier
EP3702470A3 (en) 2015-09-09 2020-10-07 The Trustees of Columbia University in the City of New York Reduction of er-mam-localized app-c99 and methods of treating alzheimer's disease
US10857145B2 (en) 2015-09-29 2020-12-08 Duke University Compositions and methods for identifying and treating dystonia disorders
BR112018007703A2 (pt) 2015-10-30 2018-11-06 Genentech Inc anticorpos, ácido nucleico isolado, métodos de produção de um anticorpo e de tratamento de um distúrbio, composição farmacêutica, terapia de combinação e uso do anticorpo
CA3005937C (en) 2015-12-13 2021-11-09 Nitto Denko Corporation Sirna structures for high activity and reduced off target
EP3423568A4 (en) 2016-03-04 2019-11-13 University Of Louisville Research Foundation, Inc. METHOD AND COMPOSITIONS FOR EX-VIVO REPRODUCTION OF VERY SMALL EMBRYONAL STEM CELLS (VSELS)
WO2017161001A1 (en) 2016-03-15 2017-09-21 Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion
WO2017173327A1 (en) 2016-03-31 2017-10-05 The Schepens Eye Research Institute, Inc. Endomucin inhibitor as an anti-angiogenic agent
US10933081B2 (en) 2016-09-21 2021-03-02 Alnylam Pharmaceuticals, Inc. Myostatin iRNA compositions and methods of use thereof
CN107858405B (zh) * 2017-10-12 2021-09-24 华南农业大学 一种测定外源dsRNA对瓢虫毒性影响的方法
US20210162007A1 (en) 2018-04-09 2021-06-03 President And Fellows Of Harvard College Modulating nuclear receptors and methods of using same
CN109183158B (zh) * 2018-08-31 2021-11-23 中国烟草总公司郑州烟草研究院 一种全长转录因子酵母单杂交文库的构建方法
CN109266677B (zh) * 2018-08-31 2021-11-23 中国烟草总公司郑州烟草研究院 一种全长转录因子酵母双杂交文库的构建方法
CN113015746A (zh) 2018-09-19 2021-06-22 拉荷亚免疫研究所 在类风湿性关节炎中的ptprs和蛋白聚糖
JP7667077B2 (ja) 2018-11-16 2025-04-22 日東電工株式会社 Ｒｎａ干渉送達製剤及び悪性腫瘍のための方法
US20220091135A1 (en) * 2019-01-04 2022-03-24 Kyoto University Test method for ulcerative colitis and primary sclerosing cholangitis
US12215382B2 (en) 2019-03-01 2025-02-04 The General Hospital Corporation Liver protective MARC variants and uses thereof
CN110229839B (zh) * 2019-06-04 2021-06-08 中国农业大学 一种提升大肠杆菌dsRNA表达产率的方法
CN110804088A (zh) * 2019-11-18 2020-02-18 维塔恩(广州)医药有限公司 巨细胞病毒相关抗原短肽及其应用
CN110746497A (zh) * 2019-11-18 2020-02-04 维塔恩(广州)医药有限公司 肺炎衣原体相关抗原短肽及其应用
EP3825408A1 (en) 2019-11-19 2021-05-26 FRAUNHOFER-GESELLSCHAFT zur Förderung der angewandten Forschung e.V. Methods of multi-species insect pest control
WO2021123920A1 (en) 2019-12-18 2021-06-24 Novartis Ag Compositions and methods for the treatment of hemoglobinopathies
AR120773A1 (es) 2019-12-18 2022-03-16 Novartis Ag Derivados de 3-(5-metoxi-1-oxoisoindolin-2-il)piperidin-2,6-diona como reductor de la actividad de la proteína wiz
EP4087652A1 (en) 2020-01-08 2022-11-16 Regeneron Pharmaceuticals, Inc. Treatment of fibrodysplasia ossificans progressiva
US20210222128A1 (en) 2020-01-22 2021-07-22 Massachusetts Institute Of Technology Inducible tissue constructs and uses thereof
WO2021173965A1 (en) 2020-02-28 2021-09-02 Massachusetts Institute Of Technology Identification of variable influenza residues and uses thereof
CN111560651B (zh) * 2020-05-22 2021-09-07 江苏省疾病预防控制中心(江苏省公共卫生研究院) 一种制备双链rna测序文库的方法
WO2022147481A1 (en) 2020-12-30 2022-07-07 Ansun Biopharma Inc. Combination therapy of an oncolytic virus delivering a foreign antigen and an engineered immune cell expressing a chimeric receptor targeting the foreign antigen
EP4359527A2 (en) 2021-06-23 2024-05-01 Novartis AG Compositions and methods for the treatment of hemoglobinopathies
WO2023012165A1 (en) 2021-08-02 2023-02-09 Universite De Montpellier Compositions and methods for treating cmt1a or cmt1e diseases with rnai molecules targeting pmp22
CN113533007B (zh) * 2021-08-06 2023-11-24 青岛瑞斯凯尔生物科技有限公司 一种抗体染色标记装置及其方法
AU2022366987A1 (en) 2021-10-14 2024-05-16 Arsenal Biosciences, Inc. Immune cells having co-expressed shrnas and logic gate systems
WO2024059618A2 (en) 2022-09-13 2024-03-21 Arsenal Biosciences, Inc. Immune cells having co-expressed tgfbr shrnas
CA3265690A1 (en) 2022-09-16 2024-03-21 Arsenal Biosciences, Inc. COMBINED GENE DISTURBANCES IMMUNE CELLS
WO2024186656A1 (en) 2023-03-03 2024-09-12 Arsenal Biosciences, Inc. Systems targeting psma and ca9
WO2025199338A1 (en) 2024-03-20 2025-09-25 Arsenal Biosciences, Inc. Systems targeting slc34a2 and tmprss4 and methods of use thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5830662A (en) * 1993-09-24 1998-11-03 The Trustees Of Columbia University In The City Of New York Method for construction of normalized cDNA libraries

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US589801A (en) * 1897-09-07 woltereck
JPS62502863A (ja) 1985-03-21 1987-11-19 ステフェン・エー・ジョンストン 寄生体由来抵抗性
US6608241B1 (en) 1985-10-29 2003-08-19 Monsanto Technology Llc Protection of plants against viral infection
NZ219472A (en) 1986-03-28 1990-08-28 Calgene Inc Regulation of phenotype in plant cells using dsdna constructs
US5017488A (en) * 1986-04-01 1991-05-21 University Of Medicine And Dentistry Of New Jersey Highly efficient dual T7/T3 promoter vector PJKF16 and dual SP6/T3 promoter vector PJFK15
US4970168A (en) * 1989-01-27 1990-11-13 Monsanto Company Virus-resistant plants
EP0473576A4 (en) * 1989-05-19 1993-03-10 Hem Research, Inc. Short therapeutic dsrna of defined structure
HUT57265A (en) 1989-11-03 1991-11-28 Zaadunie Bv Process for producing plants of diminished infection-sensitivity
US5837848A (en) * 1990-03-16 1998-11-17 Zeneca Limited Root-specific promoter
WO1991015111A1 (en) * 1990-03-30 1991-10-17 President And Fellows Of Harvard College A binary genetic system to control expression of a transgene in a transgenic animal
US5831011A (en) * 1990-07-27 1998-11-03 Mycogen Corporation Bacillus thuringiensis genes encoding nematode-active toxins
US5459252A (en) * 1991-01-31 1995-10-17 North Carolina State University Root specific gene promoter
ATE255639T1 (de) 1992-03-20 2003-12-15 Max Planck Gesellschaft Auf fungus reagierendes chimaeres gen
DE4234131C2 (de) * 1992-10-09 1995-08-24 Max Planck Gesellschaft Transgener pathogen-resistenter Organismus
CA2088379A1 (en) * 1993-01-29 1994-07-30 University Of British Columbia Biological systems incorporating stress-inducible genes and reporter constructs for environmental biomonitoring and toxicology
IL104830A (en) * 1993-02-23 2001-01-28 Yissum Res Dev Co A chimeric plasmid containing a non-structural gene for the protease of the potato virus and its various uses
DE4317845A1 (de) * 1993-05-28 1994-12-01 Bayer Ag Desoxyribonukleinsäuren
EP0770143A4 (en) * 1994-06-15 1999-09-01 Univ Columbia METHOD FOR IDENTIFYING TUMOR SUPPRESSOR GENES
US5691140A (en) * 1995-05-18 1997-11-25 New England Biolabs, Inc. Bidirectional in vitro transcription vectors utilizing a single RNA polymerase for both directions
GB9510944D0 (en) * 1995-05-31 1995-07-26 Bogaert Thierry Assays and processes for the identification of compounds which control cell behaviour,the compounds identified and their use in the control of cell behaviour
KR19990022157A (ko) * 1995-06-02 1999-03-25 앰앤드이 바이오테크 아/에스 생물학적으로 활성인 펩티드 및 핵산을 확인하는 방법
US5679551A (en) * 1995-10-31 1997-10-21 Board Of Regents, The University Of Texas System Unique double-stranded RNAS associated with the Trichomonas vaginalis virus
US5898031A (en) * 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
DE19631919C2 (de) * 1996-08-07 1998-07-16 Deutsches Krebsforsch Anti-Sinn-RNA mit Sekundärstruktur
DK1493817T3 (da) * 1996-08-09 2011-03-28 Keygene Nv Resistens over for planteskadegørere
JP2001503972A (ja) * 1996-09-18 2001-03-27 ユング，クリスチャン 線虫抵抗性遺伝子
JP4073960B2 (ja) 1996-10-03 2008-04-09 肇 加藤 炭化水素の水蒸気改質方法
US6294613B1 (en) 1996-12-18 2001-09-25 Exxonmobil Chemical Patents Inc. Compatibilized polymer blends formed using a multifunctional agent
GB9703146D0 (en) 1997-02-14 1997-04-02 Innes John Centre Innov Ltd Methods and means for gene silencing in transgenic plants
US6506559B1 (en) * 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
AUPP249298A0 (en) * 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
SI1068311T1 (sl) * 1998-04-08 2011-07-29 Commw Scient Ind Res Org Postopki in sredstva za pridobivanje modificiranih fenotipov
AR020078A1 (es) * 1998-05-26 2002-04-10 Syngenta Participations Ag Metodo para alterar la expresion de un gen objetivo en una celula de planta
GB9827152D0 (en) * 1998-07-03 1999-02-03 Devgen Nv Characterisation of gene function using double stranded rna inhibition
GB9814536D0 (en) 1998-07-03 1998-09-02 Devgen Nv Characterisation of gene function using double stranded rna inhibition
AUPR621501A0 (en) 2001-07-06 2001-08-02 Commonwealth Scientific And Industrial Research Organisation Delivery of ds rna
PL2431473T3 (pl) 2005-09-16 2017-05-31 Monsanto Technology Llc Sposoby genetycznej kontroli inwazji owadów u roślin i kompozycje do tego przeznaczone

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5830662A (en) * 1993-09-24 1998-11-03 The Trustees Of Columbia University In The City Of New York Method for construction of normalized cDNA libraries

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
FIRE A. et al., "Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans", Nature, 1998, Feb 19; 391(6669):744-5. *

Also Published As

Publication number Publication date
EP1197567B1 (en) 2008-12-31
CN1198938C (zh) 2005-04-27
US20030061626A1 (en) 2003-03-27
GB0118514D0 (en) 2001-09-19
HU230602B1 (hu) 2017-02-28
HK1029142A1 (en) 2001-03-23
WO2000001846A3 (en) 2000-06-15
JP2002519072A (ja) 2002-07-02
WO2000001846A2 (en) 2000-01-13
HUP0103571A2 (hu) 2002-01-28
CA2332619C (en) 2012-12-11
IL181727A0 (en) 2007-07-04
IL140467A (en) 2007-07-04
GB2349885A (en) 2000-11-15
ZA200007653B (en) 2002-09-19
CZ200114A3 (en) 2001-06-13
ES2320527T3 (es) 2009-05-25
CN1323354A (zh) 2001-11-21
PT1197567E (pt) 2009-04-09
EP1197567A3 (en) 2003-01-02
CA2789083C (en) 2016-03-15
NO20010019L (no) 2001-03-05
AU4907999A (en) 2000-01-24
EP2045336A3 (en) 2009-06-10
EP2374901A1 (en) 2011-10-12
KR100563295B1 (ko) 2006-03-27
DE69940219D1 (de) 2009-02-12
CA2332619A1 (en) 2000-01-13
DE29924298U1 (de) 2002-09-12
US8114980B2 (en) 2012-02-14
AU769223B2 (en) 2004-01-22
MX234065B (es) 2006-02-01
ATE419383T1 (de) 2009-01-15
GB2362885A (en) 2001-12-05
JP4353639B2 (ja) 2009-10-28
HUP0103571A3 (en) 2006-01-30
DK1197567T3 (da) 2009-05-04
EP1093526A2 (en) 2001-04-25
GB2370275A (en) 2002-06-26
IN2001DE00006A (enExample) 2007-02-09
EP1197567A2 (en) 2002-04-17
JP2009112311A (ja) 2009-05-28
EP1197567B2 (en) 2015-10-07
PL216779B1 (pl) 2014-05-30
JP5847776B2 (ja) 2016-01-27
IL140467A0 (en) 2002-02-10
KR20010074639A (ko) 2001-08-04
PL201425B1 (pl) 2009-04-30
EP1484415A2 (en) 2004-12-08
IL181727A (en) 2015-08-31
GB0020485D0 (en) 2000-10-11
GB2362885B (en) 2002-07-31
NZ509182A (en) 2004-01-30
GB2349885B (en) 2003-01-29
US20040187170A1 (en) 2004-09-23
CZ304897B6 (cs) 2015-01-07
US20040133943A1 (en) 2004-07-08
IS2816B (is) 2012-11-15
CZ303494B6 (cs) 2012-10-24
NO20010019D0 (no) 2001-01-02
CY1108920T1 (el) 2014-07-02
ES2327334T3 (es) 2009-10-28
MXPA00012955A (es) 2002-04-10
PL347978A1 (en) 2002-05-06
CN1657620A (zh) 2005-08-24
ATE433500T1 (de) 2009-06-15
EP1484415B1 (en) 2009-06-10
DE29924299U1 (de) 2002-09-12
DE69940984D1 (de) 2009-07-23
CY1109324T1 (el) 2014-07-02
EP2045336A2 (en) 2009-04-08
EP1484415A3 (en) 2008-02-13
DE1093526T1 (de) 2001-10-11
NO327729B1 (no) 2009-09-14
KR20070041607A (ko) 2007-04-18
KR20060071438A (ko) 2006-06-26
IS5802A (is) 2001-01-02
DK1197567T4 (en) 2015-12-07
IN2006DE03568A (enExample) 2007-08-31
JP2014058514A (ja) 2014-04-03
BR9911802A (pt) 2002-01-22
KR20040066200A (ko) 2004-07-23
GB9827152D0 (en) 1999-02-03
PT1484415E (pt) 2009-07-27
GB2370275B (en) 2002-11-27
ES2320527T5 (es) 2015-11-16
GB0206600D0 (en) 2002-05-01
CN1900319A (zh) 2007-01-24
CA2789083A1 (en) 2000-01-13
DK1484415T3 (da) 2009-10-12
PL213379B1 (pl) 2013-02-28

Similar Documents

Publication Publication Date Title
RU2240349C2 (ru) Способ введения dsрнк или днк, способной к продуцированию dsрнк в c.elegans (варианты), способ негативной регуляции экспрессии интересующего гена в c.elegans (варианты)
US7005423B1 (en) Characterization of gene function using double stranded RNA inhibition
AU2004200852B2 (en) Characterisation of gene function using double stranded RNA inhibition
Khan et al. A versatile site-directed gene trap strategy to manipulate gene activity and control gene expression in Caenorhabditis elegans
Lancaster How Transcription Factor Affinity Influences Target Gene Transcription
Calixto The role of the alternative splicing factor MEC-8: Its uses in creating conditional gene expression and RNAi in Caenorhabditis elegans
Kalmár Analysis of the cis-regulatory structure of developmentally regulated genes in zebrafish embryo
Hongbao Brookdale University Hospital and Medical Center, Brooklyn, New York 11212, USA ma8080@ gmail. com
Miguel Escalada Functional analysis of human enhancers using the zebrafish embryo
Ma Gene Library

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20150703